Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Leukemia, Myeloid, Acute

abstract

  • Mitoxantrone and etoposide (ME) salvage regimens have been successfully used for the treatment of primary induction failure or relapsed acute myeloid leukemia (AML). Whether the addition of intermediate dose cytarabine to ME increases complete remissions is unknown. To date, these regimens have not been directly compared. Herein, we report the response to treatment with a fixed dosing schedule of ME or MEC in 65 patients treated for primary refractory or relapsed AML with intermediate or unfavorable risk cytogenetics. Differences in CR between ME and MEC subsets were analyzed to determine the effect of cytarabine to ME.

publication date

  • April 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.leukres.2011.10.027

PubMed ID

  • 22172465

Additional Document Info

start page

  • 394

end page

  • 6

volume

  • 36

number

  • 4